Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PEITHO-3
2024-511321-54-00Phase 3Authorised
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Jun 2024
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 11
01
Overview
Phase 3, randomised, double-blind trial in pulmonary embolism (PE) comparing Reduced-dose Actilyse plus standard anticoagulation with Placebo plus standard anticoagulation (2 arms). Primary endpoint: Primary composite efficacy outcome at day 30. Planned start Jun 2024; status: authorised.
02
Drugs
tissue-plasminogen activator
03
Conditions
pulmonary embolism (PE)
Beyond the preview
Go deeper on 2024-511321-54-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-511321-54-00.